Matthew Pauls Sells 54,702 Shares of Savara Inc (NASDAQ:SVRA) Stock

Savara Inc (NASDAQ:SVRA) CEO Matthew Pauls sold 54,702 shares of the stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $3.31, for a total transaction of $181,063.62. Following the completion of the sale, the chief executive officer now directly owns 1,536,379 shares in the company, valued at approximately $5,085,414.49. This trade represents a 3.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Savara Price Performance

Shares of NASDAQ:SVRA opened at $3.22 on Wednesday. The stock’s 50 day moving average price is $3.50 and its 200 day moving average price is $4.00. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The stock has a market cap of $552.61 million, a price-to-earnings ratio of -7.49 and a beta of 0.92. Savara Inc has a 12 month low of $2.82 and a 12 month high of $5.70.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting analysts’ consensus estimates of ($0.11). Equities research analysts anticipate that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

SVRA has been the topic of several analyst reports. JMP Securities restated a “market outperform” rating and issued a $9.00 price target on shares of Savara in a research note on Tuesday, October 1st. Evercore ISI restated an “in-line” rating and issued a $5.00 target price (down from $7.00) on shares of Savara in a research report on Wednesday, November 13th. Finally, HC Wainwright reduced their price target on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $10.17.

Institutional Investors Weigh In On Savara

A number of institutional investors and hedge funds have recently bought and sold shares of SVRA. Vestal Point Capital LP raised its holdings in shares of Savara by 24.7% in the 3rd quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock worth $34,302,000 after purchasing an additional 1,600,000 shares in the last quarter. Frazier Life Sciences Management L.P. grew its position in Savara by 103.9% in the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock worth $32,874,000 after buying an additional 4,157,385 shares during the last quarter. Nantahala Capital Management LLC increased its holdings in shares of Savara by 198.2% in the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock valued at $20,879,000 after buying an additional 3,443,541 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Savara by 54.0% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 690,609 shares of the company’s stock valued at $2,928,000 after acquiring an additional 242,249 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Savara by 238.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 911,617 shares of the company’s stock worth $3,865,000 after acquiring an additional 642,259 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.